Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Lotemax Sm
Generic Name
Loteprednol Etabonate
Active Ingredient
Loteprednol EtabonateCategory
Aminoglycoside Antibacterial [EPC]
Variants
1
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 3.8 mg/g | GEL | OPHTHALMIC | 24208-507 |
Detailed information about Lotemax Sm
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Lotemax Sm, you must consult a qualified healthcare professional.
Loteprednol Etabonate is a potent ophthalmic corticosteroid used to treat ocular inflammation and dry eye. It belongs to the class of 'soft steroids,' designed for rapid metabolism to reduce the risk of intraocular pressure spikes.
The dosage of Loteprednol Etabonate varies significantly depending on the specific condition being treated and the concentration of the product prescribed. Your healthcare provider will tailor the frequency to your clinical needs.
Loteprednol Etabonate is used in pediatric patients, but safety and efficacy depend on the specific product. For example, some formulations are approved for children as young as newborns for post-operative inflammation, while others are generally reserved for older children. Dosage is typically similar to adult dosing, but a pediatric ophthalmologist will provide specific guidance based on the child's age and the severity of the condition. Clinical monitoring for intraocular pressure is even more critical in children, as they may be 'steroid responders' more frequently than adults.
Because Loteprednol Etabonate has negligible systemic absorption, no dosage adjustments are typically required for patients with kidney disease. The drug is metabolized locally in the eye.
Similar to renal impairment, liver disease does not affect the local metabolism of Loteprednol in the ocular tissues. No systemic dosage adjustment is necessary.
Clinical trials have shown no overall differences in safety or effectiveness between elderly and younger patients. However, older adults may be more prone to developing cataracts or increased eye pressure, requiring more frequent monitoring by their healthcare provider.
Proper administration is vital for the effectiveness of Loteprednol Etabonate:
If you miss a dose, apply it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not 'double up' on drops to catch up. Consistency is key to controlling ocular inflammation.
An overdose of Loteprednol Etabonate via the ocular route is unlikely to cause systemic toxicity. If a large amount is accidentally swallowed, contact a poison control center. Symptoms of chronic ocular 'overdose' (using the drops too frequently or for too long) include increased eye pressure, vision changes, and delayed wound healing.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as inflammation may return aggressively (rebound effect).
Most patients tolerate Loteprednol Etabonate well, but local reactions are relatively common due to the nature of eye drops and the underlying inflammation. Common side effects include:
These effects may occur in some patients and should be monitored:
> Warning: Stop taking Loteprednol Etabonate and call your doctor immediately if you experience any of these serious complications.
The primary concern with long-term use of Loteprednol Etabonate is the cumulative risk of glaucoma and cataracts. Most clinical protocols limit the use of Loteprednol to short bursts (2-4 weeks) unless the patient is being closely monitored by a specialist for a chronic condition like uveitis. Prolonged use also increases the risk of fungal infections of the cornea, which are notoriously difficult to treat. If you have been on this medication for more than 10 days, your healthcare provider must measure your intraocular pressure regularly.
No FDA black box warnings currently exist for Loteprednol Etabonate. However, it carries significant 'Warnings and Precautions' regarding the risk of glaucoma, cataracts, and secondary infections that are standard for all ophthalmic steroids.
Report any unusual symptoms, especially sudden changes in vision or severe eye pain, to your healthcare provider immediately.
Loteprednol Etabonate is a potent medication that requires professional supervision. It should never be shared with others, even if they have similar symptoms. It is specifically intended for the eye and should never be injected or swallowed. If your eye symptoms do not improve within 48 hours of starting treatment, you must contact your ophthalmologist, as this may indicate an infection that the steroid is not covering or is potentially masking.
There are no FDA black box warnings for Loteprednol Etabonate. It is considered one of the safer corticosteroids in its class due to its 'soft drug' metabolic profile.
If you are using Loteprednol Etabonate for more than 10 days, your healthcare provider will require:
Immediately after applying Loteprednol Etabonate, your vision may be temporarily blurred. Do not drive, use heavy machinery, or perform any activity requiring clear vision until you are certain your vision has returned to normal. This usually takes 5 to 10 minutes for drops and longer for gels or ointments.
There are no known direct interactions between alcohol and Loteprednol Etabonate. However, alcohol can sometimes exacerbate underlying inflammatory conditions or dry eye symptoms. It is best to discuss your alcohol consumption with your doctor if you have chronic eye inflammation.
For short-term use (less than a week), discontinuation is usually straightforward. However, for longer-term use or for conditions like uveitis, the dose must be tapered (gradually reduced). Stopping the medication suddenly can cause a 'rebound' of inflammation, where the symptoms return more severely than before. Always follow your doctor's specific tapering schedule.
> Important: Discuss all your medical conditions, especially a history of glaucoma or herpes simplex of the eye, with your healthcare provider before starting Loteprednol Etabonate.
There are no absolute drug-drug contraindications that would strictly prohibit the use of Loteprednol Etabonate with other medications. However, it should never be used in the presence of most viral, fungal, or mycobacterial eye infections without concurrent and effective anti-infective therapy.
Because Loteprednol Etabonate is applied topically to the eye and has negligible systemic absorption, there are no known interactions with specific foods, including grapefruit, dairy, or high-fat meals. Your diet will not affect how this medication works in your eye.
There is no evidence that common herbal supplements like St. John's Wort, Ginkgo Biloba, or Valerian root interact with Loteprednol Etabonate eye drops. However, it is always wise to inform your ophthalmologist of all supplements you are taking, as some (like high-dose Vitamin E or Omega-3s) can affect eye health or surgical outcomes.
Loteprednol Etabonate is not known to interfere with standard blood or urine laboratory tests. Because it does not reach significant levels in the bloodstream, it will not affect liver function tests, kidney function tests, or blood glucose levels (unlike oral steroids which can raise blood sugar).
For each major interaction, the primary concern is a pharmacodynamic interaction, where the effects of two drugs on the eye either cancel each other out or combine to increase the risk of side effects (like IOP elevation). The management strategy always involves close clinical monitoring and frequent eye exams.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including other eye drops or ointments.
Loteprednol Etabonate must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by your specialist include:
Patients who have had allergic reactions to other corticosteroids (such as Dexamethasone, Fluorometholone, or Prednisolone) may also be sensitive to Loteprednol Etabonate. While the chemical structure is different, the class-wide risk of hypersensitivity should be considered. If you experience sudden swelling, itching, or worsening redness after applying the drops, you may be experiencing cross-sensitivity.
> Important: Your healthcare provider will evaluate your complete medical history, especially your history of eye infections and glaucoma, before prescribing Loteprednol Etabonate.
Loteprednol Etabonate is classified as Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus (specifically, it was found to be teratogenic in rabbits and rats when given in very high oral doses), but there are no adequate and well-controlled studies in pregnant women. Because systemic absorption from the eye is minimal, the risk to the human fetus is likely very low. However, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. If you are pregnant or planning to become pregnant, discuss the use of 'punctal occlusion' (pressing the corner of the eye) to further minimize any systemic exposure.
It is not known whether topical ophthalmic administration of Loteprednol Etabonate results in sufficient systemic absorption to produce detectable quantities in human milk. Many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from steroids, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
The safety and effectiveness of certain formulations (like Lotemax 0.5% suspension) have been established for the treatment of post-operative inflammation in pediatric patients. However, its use for other conditions like allergic conjunctivitis or dry eye is less well-studied in children. Children are generally more susceptible to steroid-induced increases in intraocular pressure than adults. If a child is prescribed Loteprednol, they must be monitored very closely by a pediatric ophthalmologist.
No overall differences in safety or effectiveness have been observed between elderly and younger patients. However, the elderly are more likely to have pre-existing cataracts or glaucoma, which requires more vigilant monitoring during steroid therapy. The 'soft drug' nature of Loteprednol makes it a particularly attractive option for older patients who may be more sensitive to the side effects of traditional 'hard' steroids.
No dosage adjustment is necessary in patients with renal impairment. The drug is metabolized by esterases within the eye and does not reach the kidneys in significant active concentrations.
No dosage adjustment is necessary in patients with hepatic impairment. The primary metabolic pathway for Loteprednol Etabonate is local ocular esterase cleavage, not hepatic metabolism.
> Important: Special populations, particularly children and pregnant women, require individualized medical assessment and the lowest effective dose for the shortest possible duration.
Loteprednol Etabonate is a glucocorticoid receptor agonist. Its primary molecular mechanism involves the inhibition of the inflammatory response. Once it binds to the glucocorticoid receptor in the cytoplasm of ocular cells, the complex moves into the nucleus where it modulates gene expression. Specifically, it induces the synthesis of lipocortins (phospholipase A2 inhibitory proteins). By inhibiting phospholipase A2, Loteprednol prevents the release of arachidonic acid from cell membranes. Since arachidonic acid is the precursor for prostaglandins and leukotrienes (the primary 'messengers' of inflammation), Loteprednol effectively shuts down the inflammatory cascade at an early stage.
What makes Loteprednol unique is its 'soft drug' design. It is an analog of prednisolone etabonate where the C-20 ketone is replaced by an ester. This allows the drug to be rapidly inactivated by non-specific esterases into PJ-91 and PJ-90, which have no affinity for the glucocorticoid receptor. This rapid local metabolism is the reason for its lower propensity to raise intraocular pressure.
The anti-inflammatory effect of Loteprednol Etabonate is dose-dependent. Onset of action for allergic conditions is typically rapid (within hours), while for post-operative inflammation or uveitis, the full effect may take 24 to 48 hours. Because of its rapid metabolism, the duration of effect is relatively short, which is why four-times-daily dosing is often required to maintain therapeutic levels in the eye.
| Parameter | Value |
|---|---|
| Bioavailability | Negligible systemic bioavailability |
| Protein Binding | ~95% (systemic) |
| Half-life | Short (Rapidly metabolized in ocular tissue) |
| Tmax | Local peak in 15-30 minutes |
| Metabolism | Ocular esterases (PJ-91 and PJ-90 metabolites) |
| Excretion | Renal/Fecal (as inactive metabolites) |
Loteprednol Etabonate belongs to the therapeutic class of Ophthalmic Corticosteroids. Within this class, it is further distinguished as a 'soft steroid' or 'ester-based steroid.' It is related to other ophthalmic steroids like Prednisolone, Dexamethasone, and Rimexolone, but offers a superior safety profile regarding intraocular pressure.
Common questions about Lotemax Sm
Loteprednol Etabonate is primarily used to treat inflammatory conditions of the eye, such as redness, swelling, and itching. It is commonly prescribed after eye surgeries like cataract removal to manage post-operative pain and inflammation. It is also highly effective for seasonal allergic conjunctivitis and certain types of uveitis. Recently, specific formulations have been approved for the short-term treatment of dry eye disease flares. Because it is a 'soft steroid,' it is often preferred when doctors want to minimize the risk of increasing eye pressure.
The most common side effects are local to the eye and include temporary blurred vision, a mild stinging or burning sensation upon application, and the feeling that something is in the eye. Some patients may also experience a mild headache or increased sensitivity to light. These effects are usually brief and occur immediately after using the drops. If these symptoms persist or become severe, you should contact your eye doctor. While less common, a rise in eye pressure is a side effect that your doctor will monitor for during your exams.
There is no known direct interaction between Loteprednol Etabonate eye drops and alcohol consumption. Because the medication is applied topically to the eye and very little reaches the bloodstream, alcohol does not interfere with the drug's metabolism. However, alcohol can sometimes worsen the symptoms of dry eye or systemic inflammation, which might counteract the benefits of the treatment. It is always best to consume alcohol in moderation and consult your doctor if you have concerns about how it affects your specific eye condition.
Loteprednol Etabonate is classified as Pregnancy Category C, meaning there is limited data in humans but animal studies have shown potential risks at very high doses. In clinical practice, it is generally considered low-risk because so little of the drug enters the mother's bloodstream from the eye. However, it should only be used if clearly needed and prescribed by a doctor who has weighed the risks and benefits. To further reduce risk, patients can use a technique called 'punctal occlusion' (pressing on the tear duct) after applying the drops. Always inform your obstetrician and ophthalmologist if you are pregnant.
The time it takes for Loteprednol Etabonate to work depends on the condition being treated. For allergic reactions, many patients feel relief from itching and redness within a few hours. For post-operative inflammation or more severe conditions like uveitis, it may take 24 to 48 hours of regular use to see a significant reduction in swelling and discomfort. If your symptoms do not improve after two days of treatment, you should contact your healthcare provider. It is important to continue using the drops for the full duration prescribed, even if you feel better sooner.
You should not stop taking Loteprednol Etabonate suddenly if you have been using it for more than a few days, especially for chronic inflammatory conditions. Stopping corticosteroids abruptly can cause 'rebound inflammation,' where your symptoms return more severely than they were initially. Your doctor will typically provide a 'tapering' schedule, which involves gradually reducing the number of drops you use each day. This allows your eye's natural processes to adjust. Always follow the specific instructions provided by your ophthalmologist regarding how to finish your course of medication.
If you miss a dose of Loteprednol Etabonate, you should apply the missed drop as soon as you realize it. However, if it is nearly time for your next scheduled dose, you should skip the missed one and simply continue with your regular schedule. Do not use extra drops or 'double up' to make up for the missed dose, as this can increase the risk of side effects like eye pressure spikes. Maintaining a consistent schedule is the most effective way to manage ocular inflammation. Setting a phone alarm can be a helpful way to remember your doses.
Unlike oral corticosteroids (like prednisone tablets), Loteprednol Etabonate eye drops do not typically cause weight gain, 'moon face,' or other systemic steroid side effects. This is because the drug is designed to work locally in the eye and is rapidly broken down into inactive components before it can reach the rest of the body. The amount of steroid that reaches the systemic circulation from a few eye drops is extremely small. If you experience unexplained weight gain while using these drops, it is likely due to another cause and should be discussed with your primary care physician.
Loteprednol Etabonate can generally be used alongside other medications, but timing is important. If you are using other eye drops, you should wait at least 5 to 10 minutes between applying each medication to prevent the second drop from washing out the first. While systemic interactions are rare, you should tell your doctor about all other medications you are taking, especially other steroids or medications for glaucoma. Your doctor will monitor you to ensure that Loteprednol does not interfere with the effectiveness of your other eye treatments.
Yes, Loteprednol Etabonate is available as a generic medication in several concentrations (notably the 0.5% suspension). Generic versions are typically more cost-effective than brand-name products like Lotemax. However, not all formulations or delivery systems (like the 1% Inveltys or the 0.25% Eysuvis) may have generic equivalents available yet. When switching to a generic, ensure it is the exact concentration and form (suspension vs. gel) that your doctor prescribed, as these are not always interchangeable. Consult your pharmacist for the most current information on generic availability.
Other drugs with the same active ingredient (Loteprednol Etabonate)